Effectiveness of progesterone-primed ovarian stimulation in assisted reproductive technology: a systematic review and meta-analysis

Ling Cui1 · Yonghong Lin1 · Fang Wang1 · Chen Chen2

Received: 1 June 2020 / Accepted: 13 December 2020 / Published online: 12 January 2021
© The Author(s) 2021

Abstract

Purpose Progestin-primed ovarian stimulation (PPOS) is a new ovarian stimulation protocol that has been used over the last decade to enhance reproductive function. The purpose of this study is to evaluate whether PPOS is as effective as conventional protocols (without GnRHa downregulation).

Method Search terms included “medroxyprogesterone”, “dydrogesterone”, “progestin-primed ovarian stimulation”, “PPOS”, “oocyte retrieval”, “in vitro fertilization”, “IVF”, “ICSI”, “ART”, and “reproductive”. The selection criteria were nonrandomized studies and randomized controlled studies. For data collection and analysis, the Review Manager software, Newcastle–Ottawa Quality Assessment Scale and GRADE approach were used.

Results The clinical pregnancy rates were not significantly different in either RCTs or NRCTs [RR 0.96, 95% CI (0.69–1.33), I² = 71%, P = 0.81]; [RR 0.99, 95% CI (0.83–1.17), I² = 38%, P = 0.88]. The live birth rates of RCTs and NRCTs did not differ [RCT: RR 1.08, 95% CI (0.74, 1.57), I² = 66%, P = 0.69; NRCT: OR 1.03 95% CI 0.84–1.26), I² = 50%, P = 0.79]. The PPOS protocol had a lower rate of OHSS [RR 0.52, 95% CI (0.36–0.75), I² = 0%, P = 0.0006]. The secondary results showed that compared to the control protocol, the endometrium was thicker [95% CI (0.00–0.78), I² = 0%, P = 0.05], the number of obtained embryos was higher [95% CI (0.04–0.65), I² = 17%, P = 0.03] and more hMG was needed [in NRCT: 95% CI (307.44, 572.73), I² = 0%, P < 0.00001] with the PPOS protocol.

Conclusion The PPOS protocol produces more obtained embryos and a thicker endometrium than the control protocol, with a lower rate of OHSS and an equal live birth rate. The PPOS protocol could be a safe option as a personalized protocol for infertile patients.

Trial registration Registration at PROSPERO: CRD42020176577.

Keywords Ovarian stimulation · Assisted reproductive technology · Controlled ovarian stimulation · Clinical pregnancy rate · Live birth rate

Introduction

Progestin-primed ovarian stimulation (PPOS) was proposed by the Yanping Kuang M.D. group in 2015 [1]. Oral administration of exogenous progesterone (P), such as medroxyprogesterone acetate (MPA) and dydrogesterone (DYG) [2–5], beginning in the early follicular phase is used with gonadotropin during controlled ovarian stimulation (COS) [defined by The International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO)] [6] in IVF/ICSI treatments. PPOS can effectively prevent the activation and transmission phases of oestradiol (E2)-induced LH surges and thus serves as an alternative to conventional treatment with GnRH analogs. Prior studies have shown that the PPOS
protocol with medroxyprogesterone acetate (MPA) produces competent oocytes/embryos and achieves comparable pregnancy outcomes to those of GnRH antagonist protocols [3, 4, 7–11], as well as short-term protocols [12, 13] and mild stimulation protocols [5] (see Table 1). Coupled with the application of frozen-thawed embryo transfer (FET) and the dual trigger of GnRH agonist with low-dose hCG, the PPOS protocol also allows for nearly complete avoidance of OHSS occurrence [14, 15], since all the embryo transfers after PPOS are frozen. There are many clinical studies on PPOS protocol use in infertile women, including women who have normal ovarian function, PCOS [4, 15], poor ovarian response [7, 9], who are of advanced maternal age [5], having endometriosis [11] and donated oocytes [10]. The reported findings are variable; some studies have shown better live birth outcomes, while others showed no difference. The crucial clinical aspects of IVF protocols are efficacy and safety. Some studies have shown that the PPOS protocol may be cost-effective compared with the GnRH antagonist in planned freeze-only cycles, such as in preimplantation genetic testing or fertility preservation [11, 16]. These results are very consistent with our clinical observations, but we still need more solid evidence.

It is questionable whether PPOS has the same effect and is safer than conventional IVF protocols. The purpose of this systematic review was to investigate whether PPOS for the treatment of infertile patients achieved pregnancy outcomes that were the same as or better than those of conventional protocols (any COS protocol without gonadotrophin-releasing hormone agonist (GnRHa) downregulation). This work will hopefully provide statistical evidence for clinicians on PPOS use in the treatment of infertility.

**Methods**

**Criteria for considering studies for this review**

We performed a pairwise meta-analysis.

**Types of studies**

We included intervention studies in the form of randomized controlled trials and nonrandomized controlled trials that compared progestin-primed ovarian stimulation to other protocols.

**Types of participants**

Participants suffering from infertility.

**Types of interventions**

One of the interventions for IVF was PPOS, and the control interventions included the GnRH agonist protocol, as well as the short-term protocol and mild stimulation protocol (details of protocols are shown in Table 1).

**Types of outcome measures**

Primary outcomes:

1. Clinical pregnancy rate [6]
2. Live birth rate [6]
3. Incidence of OHSS [6]

Secondary outcomes:

1. Duration of stimulation
2. Dose of gonadotrophin for injection
3. Progestin values on trigger day (ng/ml)
4. Number of retrieved oocytes
5. Number of MII oocytes
6. Number of obtained embryos
7. Total cycle cancelation
8. Endometrial thickness

**Data collection and analysis**

**Selection of studies**

The titles and abstracts of articles were screened by two independent researchers (LC, FW) to be included or excluded. Any disagreement between the two as to which studies to include was resolved by discussion. A third author (YHL) would evaluate records when there was any unsolvable disagreement.

**Data collection process**

Data were extracted by one reviewer (LC), and checked by a second (FW). For each included study, the information collected included study design, methods, setting and time period, information about the participants (eligibility criteria), and drop-outs; interventions and outcomes, including clinical pregnancy rate, live birth rate, incidence of OHSS, duration of stimulation, dose of gonadotrophin for injection, progestin values on trigger day (ng/ml), number of retrieved oocytes, number of MII oocytes (mature oocytes), number of obtained embryos, total cycle cancelation, and endometrial thickness.
| Author (year)         | Country | Type of study       | Participants                                                                 | IVF protocol                                                                 | Intervention                                                                 |
|----------------------|---------|---------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Eftekhar et al. (2019) [4] | Iran    | RCT                 | With PCOS aged between 18 and 40 years (n = 60/each)                         | PPOS\(^2\) vs GnRH\(^2\) antagonist protocol                               | PPOS: rFSH\(^4\) (Cinnal-f Cinnagen, Iran) for injection, DYG\(^2\) for oral progesterone
|                      |         |                     |                                                                              | Antagonist protocol: cetrotide (Merck-Serono Germany) for injection           | Antagonist protocol: cetrotide (Merck-Serono Germany) for injection           |
| Chen et al. (2019) [7] | China   | RCT                 | Participants with poor responders mean age was 35 (n = 170/each)            | PPOS vs GnRH antagonist protocol                                            | PPOS: hMG\(^4\) for injection, MPA\(^2\) for oral progesterone              |
|                      |         |                     |                                                                              |                                                                              | Antagonist protocol: cetrotide + hMG                                        |
| Wen et al. (2018) [12] | China   | RCT                 | PPOS (MPA 10 mg) and short-term protocol with maximum age was 35 years (n = 31/each) | PPOS vs short-term protocol                                                 | PPOS: hMG (Lizhu Pharmaceutical Trading Co., Zhuhai, China) for injection, medroxyprogesterone acetate (MPA, Xianju Pharma, Zhejiang, China) for oral progesterone
|                      |         |                     |                                                                              |                                                                              | Short-term protocol: triptorelin (Huilin, Germany) + hMG                     |
| Begueria et al. (2019) [8] | Spain   | RCT                 | Women between 18 and 35 years (n = 91/each)                                 | PPOS vs GnRH antagonist protocol                                            | PPOS: rFSH (Gonal-F Merck, Madrid, Spain) for injection, MPA (Progevera Pfizer, Spain) for oral progesterone
|                      |         |                     |                                                                              |                                                                              | Antagonist protocol: ganirelix (Orgalutran, Merck Sharp and Dohme Limited, UK) |
| Wang et al. (2016) [15] | China   | RCT                 | Patients with PCOS. age 18–39 years (n = 60/each)                           | PPOS vs short-term protocol                                                 | PPOS: hMG (Anhui Fengyuan Pharmaceutical Co., China) for injection, MPA (Beijing Zhong Xin Pharmaceutical, China) for oral progesterone
|                      |         |                     |                                                                              |                                                                              | Short-term protocol: hMG for injection                                       |
| Iwami et al. (2018) [3] | Japan   | Prospective nonrandomized controlled study | Age younger than 41 years 125 in study group and 126 in control group | PPOS vs GnRH antagonist protocol                                            | PPOS: hMG (Teizo, ASKA Pharmaceutical Co., Ltd., Tokyo, Japan) for injection, DYG (Duphaston, Abbott Healthcare, Tokyo, Japan) for oral progesterone
|                      |         |                     |                                                                              |                                                                              | Antagonist protocol: ganirelix (Ganirelix MSD, Tokyo, Japan) or Cetrotide (EMD-Serono, Tokyo, Japan) |
| Wang et al. (2018) [13] | China   | Retrospective cohort study | 1107 cycles from the PPOS protocol and 969 cycles from the GnRH-a short protocol | PPOS vs short-term protocol                                                 | PPOS: hMG (Anhui Fengyuan Pharmaceutical Co., Ltd., Hefei, China) for injection, utrogestan (Laboratories Besins International, Paris, France) for oral progesterone
|                      |         |                     |                                                                              |                                                                              | Short-term protocol: cetrotelix (Decapeptyl, Ferring Pharmaceuticals, Germany) |
| Author (year)               | Country | Type of study                | Participants                                                                 | IVF protocol                                      | Intervention                                                                 |
|-----------------------------|---------|------------------------------|------------------------------------------------------------------------------|---------------------------------------------------|------------------------------------------------------------------------------|
| Huang et al. (2019) [9]     | China   | Retrospective cohort study   | Poor ovarian responders 63 cycles from the PPOS protocol and 123 cycles from the GnRH-a short protocol | PPOS vs GnRH antagonist protocol                  | PPOS: hMG (Anhui Fengyuan Pharmaceutical Co, China) for injection, MPA (Beijing Zhong Xin Pharmaceutical, China) Antagonist protocol: cetrorelix (Decapeptyl, Ferring Pharmaceuticals, Germany) |
| Peng et al. (2019) [5]      | China   | retrospective cohort study   | Women with ages ≥ 40 years. 122 cycles mild stimulation group and PPOS group (47 cycles) | PPOS vs mild stimulation protocol                 | PPOS: hMG (Lizhu Pharmaceutical Trading Co., Zhuhai, China) for injection, DYG (Duphaston; Abbott Biologicals B.V., Netherlands) for oral progesterone The mild stimulation protocol: CC (Codal Synto Ltd., Cyprus) + hMG |
| Yildiz et al. (2019) [10]   | Turkey  | Retrospective cohort study   | 103 donors, mean age 25 years 49 PPOS group 54 control group                 | PPOS vs GnRH antagonist protocol                  | PPOS: rFSH (Gonal F, Merck Serono, Switzerland) for injection, MPA (Tarlusal, Deva) for oral progesterone Antagonist protocol: (Cetrotide, Merck Serono) |
| Mathieu d’Argent et al. (2020) [11] | France  | Retrospective cohort study   | Age < 40 years, with endometriosis (n = 54/each)                              | PPOS vs GnRH antagonist protocol                  | PPOS: rFSH for injection, desogestrel for oral progesterone Antagonist protocol: (Ganirelix, orgalutran MSD France) |

1RCT: randomized controlled trial  
2PPOS: progestin-primed ovarian stimulation  
3GnRH: gonadotropin-releasing hormone  
4FSH: recombinant human follicle stimulating hormone  
5DYG: dydrogesterone  
6hMG: human menopausal gonadotropin  
7MPA: medroxyprogesterone acetate  
8CC: clomiphene citrate
Search methods for identification of studies

This study was based on the PRISMA guidelines for systematic review and meta-analysis [17]. The electronic databases used were MEDLINE, EMBASE, and the Cochrane Library from 2010 to 13th March 2020 without limitation of region, language, or publication type. Specific strategies for electronic search at the database used a combination of (MeSH): (((medroxyprogesterone or Dydrogesterone) or progestin-primed ovarian stimulation) or PPOS)) and (((oocyte retrieval rate) or IVF) or ICSI) or ART). The following keywords “medroxyprogesterone”, “dydrogesterone”, “progestin-primed ovarian stimulation”, “PPOS”, “oocyte retrieval”, “IVF”, “ICSI”, “ART”, and “reproductive” were used in the search. Intervention studies including prospective controlled study, retrospective cohort study, nonrandomized studies with comparison groups (NRCTs), and randomized controlled trial were included. The inventions of the control group included short-term protocol, GnRH antagonist protocol, and mild stimulation protocols (any cos protocol without GnRHa downregulation). The strategies for electronic search at the database used a combination of (MeSH): (((medroxyprogesterone or Dydrogesterone) or progestin-primed ovarian stimulation) or PPOS)) and (((oocyte retrieval rate) or IVF) or ICSI) or ART).

We excluded the following studies: (1) self-controlled study; (2) books, conferences, review articles, editorial, notes, thesis, case series, letters, posters, and case reports; (3) unreliable extracted data, overlapped datasets, and paragraphs of only abstract available.

Assessment of risk of bias in individual studies

Quality of studies

The Cochrane collaboration tools were used to assess the risk of bias in randomized controlled trials [18]. The Cochrane Collaboration risk of bias tool includes random sequence generation (selection bias), allocation sequence concealment (selection bias), blinding of participants and personnel performance bias (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other bias. The reviewers rated the quality of the included studies as low risk, unclear risk or high risk.

Newcastle–Ottawa Scale (NOS) was used to assess the quality of nonrandomized controlled studies in meta-analyses [19]. The NOS is useful, reliable, complementary tools for appraising methodological quality of medical education research [20]. The NOS contains eight items. The items are categorized into three dimensions including selection, comparability, and outcomes of studies. The NOS ranges from zero to nine stars as follows: selection of the study group (up to 4 stars/points), comparability of cohorts (up to 2 stars/points), and ascertainment of outcome (up to 3 stars/points). High-quality studies achieve more than seven stars, medium-quality studies between four and six stars, and poor-quality studies less than four stars.

Data synthesis

All data were entered into the analysis system (Review Manager, version 5.2). We used the risk ratio (RR) and 95% confidence intervals (CIs) for variables with dichotomous data for RCTs and odds ratios (ORs) for nonrandomized studies. For these variables, the weighted summary RR was calculated using the Mantel–Haenszel method. For continuous data, the mean difference (MD) was calculated and corrected according to the sample bias.

We constructed ‘Summary of findings’ tables using GRADE-pro [21]. We summarized and graded the certainty of the evidence for critical outcomes (clinical pregnancy rate, live birth rate, OHSS, duration of stimulation, dose of gonadotrophin for injection, number of retrieved oocytes, number of obtained embryos, and endometrial thickness).

Subgroup analysis and investigation of heterogeneity

Higgins $I^2$ values [22] were used to assess statistical heterogeneity between studies and values of $I^2 \leq 25\%$ which were indicative of low heterogeneity.

We used a fixed-effect model in the analysis, as our results were all homogeneous according to the chi-squared test and $I^2 \leq 50\%$. The random-effect model was used in the analysis, our results were all homogeneous according to the chi-squared test, and $50\% \leq I^2 \leq 70\%$ was taken to indicate substantial statistical heterogeneity. If the chi-squared test result and $I^2$ were $\geq 70\%$, where the heterogeneity was too large and not suitable for combined analysis, we performed a subgroup analysis. The effectiveness of HMG versus recombinant FSH in women undergoing ovarian stimulation for IVF/ICSI demonstrated a significant difference in the live birth rate [23, 24]. We performed subgroup analysis for clinical pregnancy rate (primary outcome), live birth rate (primary outcome), and dose of sex hormones for injection (secondary outcome) considering the different types of sex hormones for injection (rFSH or hMG) according to clinical experience.

Sensitivity analysis

For outcomes such as the number of MII oocytes, we examined the sensitivity versus risk of bias (by excluding one
study [12] with unclear risks of bias from the analysis of selection bias, performance bias, detection bias, attrition bias, selective reporting, and reporting bias. We also assessed the outcome of gonadotrophin subgroup (hMG) sensitivity to risk of bias (by excluding one study [12] with unclear risks of bias from the analysis of selection bias, performance bias, detection bias, attrition bias, selective reporting, and reporting bias and one study [15] with a large difference in the mean ± SD (2072.5 ± 467.86 vs. 1501.25 ± 68.18).

**Results**

**Results of the search**

We identified a total of 117 records from the electronic database searches. Deduplication and removal of all irrelevant records were performed. After the titles and abstracts were screened, 86 irrelevant records were excluded. Of the remaining 24 studies, we excluded 13 records. Details of the selection process for studies are summarized in the PRISMA flow diagram (Fig. 1). There were five RCTs, one nonrandomized study and five retrospective cohort studies (Table 1).

**Description of populations and interventions**

Table 1 provides brief details of populations and interventions. Two RCTs [4, 15] included PCOS participants, and the studies by Chen et al. [7] and Huang et al. [9] included participants with poor responders. Wen et al. [12] and Begueria et al. [8] included participants with a maximum age of 35 years. Iwami et al. [3] and Mathieu d’Argent et al. [11] included participants with maximum ages of 41 and 40 years. Peng et al. [5] included participants aged ≥ 40 years. Yildiz et al. [10] included participants with donor oocytes.

**Quality of studies**

The quality of the studies included varied widely. Randomized control trials (RCTs) were assessed for their methodological quality using the Cochrane Risk of Bias Tool. The full details of the risk of bias assessment for the randomized studies are given below (Fig. 2). Three of five RCTs had four or five out of seven domains with a low risk of bias, but one study [12] had six unclear risks of bias. Three of six nonrandomized studies achieved seven stars and were judged as high quality. The other three achieved four to six stars and were judged to be of medium quality. Full details of the Newcastle–Ottawa Scale (NOS) scores for the nonrandomized studies are provided in Table 2.

**Quality of the evidence**

The GRADE approach aims to evaluate the quality of the evidence for each major outcome. It also takes into consideration the results from the trial sequential analyses (see summary of findings for the main comparison, Table 3). For the primary outcomes of the clinical pregnancy rate, the quality of the RCT groups and subgroups was moderate, while the nonrandomized studies were low. For the live birth rate, the quality of the RCT groups and subgroups was high, while the nonrandomized studies were low. For OHSS, the quality was high. The quality of each secondary outcome is described in detail in Table 3.

**Primary outcomes**

1. **Clinical pregnancy rate**

Five RCTs showed that the clinical pregnancy rate with the PPOS protocol was not different from that with the control group [RR 0.96, 95% CI (0.69–1.33), I² = 71%, P = 0.81].

For I² ≥ 70%, the heterogeneity was too large and not suitable for combined analysis. Analysis of the effectiveness of hMG versus recombinant FSH in women undergoing ovarian stimulation for IVF/ICSI demonstrated a significant difference in live birth rates [23, 24]. We performed subgroup analysis for the clinical pregnancy rate (primary outcome). Two RCTs in the rFSH subgroup showed that the PPOS protocol had a lower clinical pregnancy rate than the control group [RR 0.64, 95% CI (0.49–0.85), I² = 0%, P = 0.002]. Three RCTs showed that in the hMG subgroup, the PPOS protocol led to a higher clinical pregnancy rate than the control group [RR 1.22 95% CI (0.99–1.5), I² = 0%, P = 0.06], and the difference was very close to being statistically significant.

The results of five NRCTs did not show any significant difference in the clinical pregnancy rate between the two groups [RR 0.99, 95% CI (0.83–1.17), I² = 38%, P = 0.88].

2. **Live birth rate**

The live birth rates were not different between groups in three RCTs [RR 1.08, 95% CI (0.74, 1.57), I² = 66%, P = 0.69]. Additionally, the results of one NRCT showed that there was no difference between the two groups [OR 1.03 95% CI 0.84–1.26, I² = 50%, P = 0.79] (Fig. 3).

3. **OHSS**

Only two RCTs described the incidence of OHSS, and the results showed that the PPOS protocol had a lower rate of OHSS [RR 0.52, 95% CI (0.36–0.75), I² = 0%, P = 0.0006] (Fig. 3). The result was statistically significant.
Fig. 1 PRISMA flow diagram of study selection for the systematic review and meta-analysis

117 of records identified through database searching

7 of records after duplicates removed

110 of records screened

86 of irrelevant records excluded

12 of full-text articles excluded

(2 self-controlled studies)

(3 PPOS with or without clomiphene citrate)

(6 PPOS with different progesterone)

(1 PPOS VS GnRHa-Long Protocol)

24 of full-text articles assessed for eligibility

12 of studies included in qualitative synthesis

1 study was protocol without outcomes

11 of studies included in quantitative synthesis (meta-analysis)
Fig. 2 Risk of bias assessment for the randomized studies

Table 2 Newcastle–Ottawa risk of bias for included NRCTs

| Author (year)             | Selection of study groups score | Comparability of groups score | Outcome score | Total NOS score | Risk of bias |
|---------------------------|---------------------------------|------------------------------|---------------|-----------------|--------------|
| Iwami et al. (2018) [3]   | 3                               | 1                            | 1             | 5 stars         | Medium       |
| Wang et al. (2018) [13]   | 3                               | 1                            | 3             | 7 stars         | Low          |
| Huang et al. (2019) [9]   | 3                               | 1                            | 2             | 6 stars         | Medium       |
| Peng et al. (2019) [5]    | 3                               | 1                            | 1             | 5 stars         | Medium       |
| Yildiz et al. (2019) [10] | 3                               | 2                            | 2             | 7 stars         | Low          |
| Mathieu d’Argent E et al. (2020) [11] | 4 | 1 | 2 | 7 stars | Low |
Secondary outcomes

4. Duration of stimulation (day)
   Data from both RCTs (MD 0.03 lower, 95% CI (−0.37–0.31), $I^2 = 44\%$, $P = 0.85$) and nonrandomized trials (MD 0.12 higher, 95% CI (−0.51–0.75), $I^2 = 61\%$, $P = 0.71$) showed that the duration of stimulation between the two groups was nearly the same. The slight difference was not statistically significant (Fig. 4).

5. Dose of gonadotrophin for injection (IU)
   We performed preplanned subgroup analysis of the dose of gonadotrophin for two different kinds of gonadotrophin. Two RCTs in the rFSH subgroup showed that the mean difference (MD) in dose for PPOS in the rFSH subgroup was 55.1 higher [95% CI (−48.35–158.56), $I^2 = 0\%$, $P = 0.30$]. Only one RCT showed that the MD in dose of the PPOS protocol was 121.3 lower in the hMG subgroup [95% CI (−258.76–16.16), $P = 0.08$]. These differences were not statistically significant. The results of NRCTs showed that the MD in the subgroup of rFSH was 116.47 lower [95% CI (−480–247.24), $I^2 = 0\%$, $P = 0.53$]. NRCTs in the hMG subgroup showed that the MD for the PPOS protocol was 440.08 higher [95% CI (307.44, 572.73), $I^2 = 61\%$, $P = 0.71$].

Table 3  Summary of findings for the main comparison

| Outcome                              | Illustrative comparative risksa (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) |
|--------------------------------------|----------------------------------------|--------------------------|-------------------------------|---------------------------------|
|                                      | Assumed risk                           | Corresponding risk       |                               |                                 |
| Control                              | Clinical pregnancy rate                | RR 0.94 (0.89–0.99)      | 564                           | Moderatea                        |
| 372 per 1000                         | 365 per 1000                           | (257–493)                | (5 studies)                   |                                 |
| Moderate                             |                                        |                         |                               |                                 |
| 419 per 1000                         | 402 per 1000                           | (289–537)                | (5 studies)                   |                                 |
| Non-randomized Clinical pregnancy rate| Study population                       | OR 0.50 (0.43–0.60)      | 2560                          | Low                             |
| 451 per 1000                         | 475 per 1000                           | (363–715)                | (5 studies)                   |                                 |
| Moderate                             |                                        |                         |                               |                                 |
| 435 per 1000                         | 420 per 1000                           | (449–534)                | (5 studies)                   |                                 |
| RCT-Clinical pregnancy rate          | Study population                       | RR 0.64 (0.51–0.81)      | 400                           | Moderatea                        |
| 417 per 1000                         | 287 per 1000                           | (205–385)                | (4 studies)                   |                                 |
| Moderate                             |                                        |                         |                               |                                 |
| 376 per 1000                         | 241 per 1000                           | (169–320)                | (3 studies)                   |                                 |
| RCT-Clinical pregnancy rate of subgroup of rFSH | Study population | RR 1.22                      | 564                           | Moderatea                        |
| 340 per 1000                         | 415 per 1000                           | (337–511)                | (3 studies)                   |                                 |
| Moderate                             |                                        |                         |                               |                                 |
| 419 per 1000                         | 511 per 1000                           | (457–635)                | (3 studies)                   |                                 |
| RCT-Live birth rate                  | Study population                       | RR 1.84 (0.74–4.57)      | 855                           | High                            |
| 280 per 1000                         | 209 per 1000                           | (159–432)                | (3 studies)                   |                                 |
| Moderate                             |                                        |                         |                               |                                 |
| 275 per 1000                         | 207 per 1000                           | (204–432)                | (3 studies)                   |                                 |
| Study population                     |                  |                          |                               |                                 |

GRADE Working Group grades of evidence

- **High quality**: Further research is very unlikely to change our confidence in the estimate of effect.
- **Moderate quality**: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
- **Low quality**: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
- **Very low quality**: We are very uncertain about the estimate.

*aOne study with unclear risks of bias from selection bias, performance bias, detection bias, attrition bias, selective reporting and reporting bias.

Chi-square test and $I^2 = 61\%$ was taken to indicate substantial statistical heterogeneity.

$^a$Increased dosage is better.
### Primary outcomes

#### 1. Clinical pregnancy rate

| Study or Subgroup | PPOS Events | Control Events | Risk Ratio M.H. Fixed, 95% CI | Risk Ratio M.H. Random, 95% CI |
|-------------------|-------------|----------------|-------------------------------|-------------------------------|
| **1.1 RCT-clinical pregnancy rate** | | | | |
| 1 (RCT) Ebeihak 2019 | 85 41 | 15 51 | 10.0% | 0.50 [0.21, 1.17] |
| 2 (RCT) Chen Q 2019 | 48 170 | 39 170 | 22.3% | 1.23 [0.85, 1.77] |
| 3 (RCT) Wen X 2019 | 17 34 | 13 31 | 17.0% | 1.19 [0.70, 2.03] |
| 4 (RCT) Beegun R 2019 | 47 153 | 71 156 | 24.7% | 0.87 [0.56, 1.39] |
| 5 (RCT) Wang Y 2016 | 49 75 | 45 84 | 25.9% | 1.22 [0.94, 1.59] |
| **Total (95% CI):** 473 491 | | | 96 [0.69, 1.33] |
| Total events | 1107 | 158 | 100.0% | 0.50 [0.21, 1.17] |
| Heterogeneity: $I^2 = 0.09$, $Q = 13.05$, $df = 4$ ($P = 0.008$, $I^2 = 71$%)
| Test for overall effect: $Z = 2.05$ ($P = 0.01$) |

| **1.2 RCT-FFSH subgroup** | | | | |
| 1 (RCT) Ebeihak 2019 | 85 41 | 15 51 | 15.9% | 0.50 [0.21, 1.17] |
| 4 (RCT) Beegun R 2019 | 47 153 | 71 156 | 84.1% | 0.67 [0.50, 0.90] |
| **Total (95% CI):** 194 | 206 | 100.0% | 0.64 [0.46, 0.85] |
| Total events | 86 | 100 | 0.0% | 0.50 [0.21, 1.17] |
| Heterogeneity: $I^2 = 0.09$, $Q = 13.05$, $df = 4$ ($P = 0.008$, $I^2 = 71$%)
| Test for overall effect: $Z = 3.11$ ($P = 0.002$) |

| **1.3 RCT-HMG subgroup** | | | | |
| 2 (RCT) Chen Q 2019 | 48 170 | 39 170 | 41.0% | 1.23 [0.85, 1.77] |
| 3 (RCT) Wen X 2019 | 17 34 | 13 31 | 14.3% | 1.19 [0.70, 2.03] |
| 5 (RCT) Wang Y 2016 | 49 75 | 45 84 | 44.7% | 1.22 [0.84, 1.75] |
| **Total (95% CI):** 279 | 285 | 100.0% | 1.22 [0.95, 1.58] |
| Total events | 97 | 87 | 0.0% | 1.23 [0.85, 1.77] |
| Heterogeneity: $I^2 = 0.09$, $Q = 13.05$, $df = 4$ ($P = 0.008$, $I^2 = 71$%)
| Test for overall effect: $Z = 1.91$ ($P = 0.06$) |

| **1.4 NRCT-clinical pregnancy rate** | | | | |
| 10 Iydiz S 2019 | 55 86 | 66 105 | 8.3% | 1.05 [0.58, 1.90] |
| 6 Iyami N 2018 | 103 195 | 180 202 | 10.0% | 1.14 [0.77, 1.69] |
| 7 Wang H 2016 | 872 1107 | 785 969 | 69.9% | 0.67 [0.70, 1.03] |
| 8 Huang S 2019 | 19 50 | 25 112 | 3.7% | 2.13 [0.03, 4.40] |
| 9 Peng Q 2019 | 3 18 | 7 56 | 1.1% | 1.40 [0.02, 6.09] |
| **Total (95% CI):** 1456 | 1444 | 100.0% | 0.95 [0.83, 1.17] |
| Total events | 97 | 87 | 0.0% | 1.05 [0.58, 1.90] |
| Heterogeneity: $I^2 = 0.09$, $Q = 13.05$, $df = 4$ ($P = 0.017$, $I^2 = 38$%)
| Test for overall effect: $Z = 0.18$ ($P = 0.88$) |

#### 2. Live birth rate

| Study or Subgroup | PPOS Events | Control Events | Risk Ratio M.H. Fixed, 95% CI | Risk Ratio M.H. Random, 95% CI |
|-------------------|-------------|----------------|-------------------------------|-------------------------------|
| **2.1 RCT-live birth rate** | | | | |
| 2 (RCT) Chen Q 2019 | 37 170 | 31 170 | 20.8% | 1.19 [0.78, 1.83] |
| 4 (RCT) Beegun R 2019 | 31 153 | 42 153 | 31.8% | 0.74 [0.49, 1.11] |
| 5 (RCT) Wang Y 2016 | 44 75 | 36 84 | 37.6% | 1.37 [0.01, 1.87] |
| **Total (95% CI):** 398 | 407 | 100.0% | 1.00 [0.74, 1.57] |
| Total events | 112 | 110 | 0.0% | 1.19 [0.78, 1.83] |
| Heterogeneity: $I^2 = 0.09$, $Q = 13.05$, $df = 4$ ($P = 0.008$, $I^2 = 71$%)
| Test for overall effect: $Z = 0.40$ ($P = 0.69$) |

| **2.2 NRCT-live birth rate** | | | | |
| 10 Iydiz S 2019 | 43 86 | 51 105 | 14.2% | 1.09 [0.60, 1.87] |
| 7 Wang H 2016 | 659 872 | 599 785 | 83.1% | 0.96 [0.77, 1.20] |
| 8 Huang S 2019 | 16 50 | 20 112 | 4.5% | 2.10 [0.01, 4.60] |
| **Total (95% CI):** 1008 | 1002 | 100.0% | 1.03 [0.84, 1.26] |
| Total events | 870 | 870 | 0.0% | 1.09 [0.60, 1.87] |
| Heterogeneity: $I^2 = 0.09$, $Q = 13.05$, $df = 4$ ($P = 0.014$, $I^2 = 50$%)
| Test for overall effect: $Z = 0.26$ ($P = 0.79$) |

#### Primary outcomes

#### 3. OHGS

| Study or Subgroup | PPOS Events | Control Events | Risk Ratio M.H. Fixed, 95% CI | Risk Ratio M.H. Random, 95% CI |
|-------------------|-------------|----------------|-------------------------------|-------------------------------|
| **1 (RCT) Ebeihak 2019** | | | | |
| 10 Iydiz S 2019 | 22 60 | 41 60 | 94.3% | 0.54 [0.37, 0.78] |
| **Total (95% CI):** 120 | 120 | 100.0% | 0.52 [0.36, 0.75] |
| Total events | 43 | 43 | 0.0% | 0.52 [0.36, 0.75] |
| Heterogeneity: $I^2 = 0.09$, $Q = 13.05$, $df = 4$ ($P = 0.008$, $I^2 = 71$%)
| Test for overall effect: $Z = 3.44$ ($P = 0.006$) |

---

*Fig. 3 Forest plot of studies of primary outcomes*
**Fig. 4** Forest plot of studies of secondary outcomes

### Secondary outcomes

#### 4. Duration of stimulation

| Study or Subgroup | PPPOS | Control | Mean Difference | N (Fixed, 95% CI) | IV, Random (95% CI) |
|-------------------|-------|---------|----------------|------------------|--------------------|
| **Mean Difference** |       |         |                |                  |                    |
| **Total**         | 376   | 377     |                |                  | 100.0%             |

Heterogeneity: $I^2 = 3.22$, $d.f. = 3$ ($P = 0.15$), $F = 44$

Test for overall effect: $Z = 0.18$ ($P = 0.95$)

#### 5. Dose of gonadotropin

| Study or Subgroup | PPPOS | Control | Mean Difference | N (Fixed, 95% CI) | IV, Random (95% CI) |
|-------------------|-------|---------|----------------|------------------|--------------------|
| **Mean Difference** |       |         |                |                  |                    |
| **Total**         | 179   | 179     |                |                  | 100.0%             |

Heterogeneity: Not applicable

Test for overall effect: $Z = 1.73$ ($P = 0.08$)

#### 6. Progestin, values on trigger day (mg/ml)

| Study or Subgroup | PPPOS | Control | Mean Difference | N (Fixed, 95% CI) | IV, Random (95% CI) |
|-------------------|-------|---------|----------------|------------------|--------------------|
| **Mean Difference** |       |         |                |                  |                    |
| **Total**         | 236   | 236     |                |                  | 100.0%             |

Heterogeneity: $I^2 = 0.53$ (d.f. = 2) ($P = 0.77$), $F = 0$

Test for overall effect: $Z = 0.60$ ($P = 0.02001$)
The difference was statistically significant (Fig. 4).

6. Progestin values on trigger day (ng/ml)
   Data from both RCTs [MD 0.03 lower, 95% CI (−0.08–0.02), $I^2 = 0\%$, $P = 0.25$] and NRCTs [MD 0.01 lower 95% CI (−0.27–0.26), $I^2 = 0\%$, $P = 0.94$] (Fig. 4) showed that the progestin values on the trigger day between the two groups were nearly the same. The slight difference was not statistically significant.

7. Number of retrieved oocytes
   Data from both RCTs [MD 0.2 higher, 95% CI (−0.32–0.72), $I^2 = 31\%$, $P = 0.45$] and NRCTs [MD 0.05 lower 95% CI (−0.33–0.24), $I^2 = 0\%$, $P = 0.76$] (Fig. 5) showed that the number of retrieved oocytes between the two groups was nearly the same.

8. Number of MII oocytes
   Data from either RCTs [MD 0.05 higher, 95% CI (−0.56–0.65), $I^2 = 61\%$, $P = 0.88$] or NRCTs [MD 0.19 lower 95% CI (−0.83–0.45), $I^2 = 0\%$, $P = 0.56$] (Fig. 5)
showed that the number of MII oocytes between the two groups was nearly the same.

9. Number of obtained embryos

Only the five RCTs (Fig. 5) had the date of the number of obtained embryos, and the result showed that the PPOS protocol had more obtained embryos [MD 0.35 higher 95% CI (0.04–0.65), \( I^2 = 17\% \), \( P = 0.03 \)]. The result was statistically significant.

10. Total cycle cancelation

Data from both RCTs [95% CI (0.50–163.58), \( P = 0.14 \)] and NRCTs [95% CI (−0.07–0.04), \( I^2 = 52\% \), \( P = 0.66 \)] (Fig. 6) showed that there were no significant differences in the total cycle cancelation rates between the two groups.

11. Endometrial thickness (millimeter, mm)

Data from RCTs showed that the endometrium was thicker with the PPOS protocol than with the control protocol [MD 0.39 mm, higher 95% CI (0.00–0.78), \( I^2 = 0\% \), \( P = 0.05 \)], and difference was statistically significant. Data from NRCTs (Fig. 6) showed that the endometrium was thinner with the PPOS protocol than with the control group [MD 0.14 mm lower 95% CI (−0.78–0.49), \( P = 67\% \), \( P = 0.66 \)], though the difference was not statistically significant.

Discussion

The results of this meta-analysis showed that the PPOS protocol had more obtained embryos and a thicker endometrium than the control protocol, with a lower rate of OHSS. There were no significant differences in the live birth rate, duration of stimulation, progestin values on trigger day (ng/ml), number of retrieved oocytes, number of MII oocytes, or total cycle cancelation rates between the two groups.

In the rFSH subgroup, the clinical pregnancy rate was lower in the PPOS group than in the control group, and the result was statistically significant. Three RCTs showed that
the hMG subgroup, the clinical pregnancy rate of the PPOS protocol was higher than that of the control group, and the difference was near statistical significance ($P = 0.06$). The quality of the evidence (GRADE) was moderate. The results of the RCT of the rFSH/hMG subgroups showed that there was no significant difference in the dose of rFSH/hMG between the two groups, and the quality of the evidence (GRADE) was high. Only NRCTs in the hMG subgroup showed that the dose of hMG in the PPOS protocol was higher. Data from RCTs showed that the PPOS protocol had a thicker endometrium, and the quality of evidence was high with a significant difference. While NRCTs showed that the endometrium was thinner with the PPOS protocol, there was no significant difference, and the quality of evidence (GRADE) was low.

The prevalence of infertility is high around the world, and it is estimated that 1 out of 4 couples are infertile [25]. ART has developed quite rapidly over recent years, and there is still an unmet need for ovarian stimulation protocols with improved efficacy, safety, and convenience. New protocols, such as GnRH antagonist protocols and mild stimulation protocols, have been proposed over the last decade. Progestin-primed ovarian stimulation (PPOS) is also one of these new ovarian stimulation protocols. Some studies [26, 27] have suggested that compared with conventional ovarian stimulation methods, the PPOS protocol neither compromises neonatal outcomes of IVF newborns nor increases the prevalence of congenital malformations. This is the first meta-analysis to examine the effect of the PPOS protocol in ART. According to our review, the safety and effectiveness of PPOS are confirmed.

Poor ovarian response (POR) to ovarian hyperstimulation is one of the greatest challenges in assisted reproduction technology. According to the report from the Society for Assisted Reproductive Technology (SART) in 2018 in the USA, in women considered to be poor responders, there is fair evidence to support the recommendation that mild ovarian stimulation is cost-effective, although live birth rates are extremely low among both women undergoing the mild ovarian stimulation and those undergoing conventional IVF [28]. A retrospective study (Peng et al.) [5] showed no significant difference in the clinical pregnancy rates between the mild stimulation (12.5%) and PPOS groups (16.7%). The average numbers of oocytes and viable embryos and the live birth rates were comparable to those in the GnRH antagonist group. Although the PPOS protocol did not improve the clinical pregnancy rates of POR patients, it might be an option for personalized protocols.

In 2015, Dr. Kuang et al. [1] proposed the PPOS protocol such as medroxyprogesterone acetate (MPA), dydrogesterone [2–5, 28], or utrogestan [13, 29, 30]. In PPOS protocols, all of these options are sufficient to prevent an untimely LH rise. As DYG has been extensively used worldwide for the treatment of threatened miscarriage and recurrent miscarriage, DYG administration in PPOS protocols produces a comparable number of top-quality embryos and pregnancy outcomes compared with MPA [28]. However, further randomized controlled trials are needed to confirm this conclusion.

Recombinant follicle-stimulating hormone (rFSH) and human menopausal gonadotropin (uHMG) are widely used for controlled ovarian stimulation (COS). rFSH treatment results in a higher oocyte yield per cycle than human meno- pausal gonadotropin treatment [31, 32]. Different clinics choose different GN doses in PPOS protocols. From this meta-analysis, we conclude that there is no difference in the live birth rate. In the subgroup analysis, the hMG subgroup had a better clinical pregnancy rate, while the rFSH group had a lower clinical pregnancy rate than the control group. It may be suggested to choose hMG for COS in the PPOS protocol. A cost-effectiveness study [16] showed that PPOS protocols were cost-effective when freeze-only was planned for preimplantation genetic testing or fertility-preservation cycles, where a GnRH antagonist protocol would otherwise be used. In addition, this study cannot accurately specify drugs for PPOS protocols. More RCTs should be performed to evaluate the best drug candidates for individual infertile patients.

The strength of this meta-analysis lies in the strict methodology guided by PRISMA guidelines.

Additionally, the quality of the RCTs was evaluated using the Cochrane Handbook method as a way to enhance external validity. The quality of NRCTs was evaluated using the Newcastle–Ottawa Scale. Furthermore, we graded the certainty of the evidence for critical outcomes by GRADE-pro.

**Limitations of the review**

Only five RCTs were included in our meta-analysis. The outcomes of NRCT by GRADE-pro were quite low. Furthermore, 6 of the 11 records included were from China. Progestin-primed ovarian stimulation (PPOS) was first proposed by the Yanping Kuang M.D. group in 2015. Over the last two years, many centers around the world have begun to choose PPOS.

**Conclusion**

The PPOS protocol produces more obtained embryos and a thicker endometrium than the control group, with a lower rate of OHSS and equal clinical pregnancy rate, live birth rate, duration of stimulation, progestin value on trigger
day (ng/ml), number of retrieved oocytes, number of MII oocytes, and total cycle cancelation rate. In the subgroup analysis, the hMG subgroup had a better clinical pregnancy rate, while the rFSH group had a lower clinical pregnancy rate than the control group. It may be suggested to choose hMG for COS in the PPOS protocol. More RCTs should be performed to evaluate the best ones for respective infertile patients.

Acknowledgements Professor Fang Wang and Professor Chen Chen contributed equally to this work.

Author contributions Dr. LC was involved in the design and conduct of the review, data analysis, and drafting of the manuscript. Professor YHL was involved in and supervised the data analysis and critical discussion. Professor FW was involved in the design and conduct of the review, checked the data extraction, revised the manuscript, and validated the final version for submission. Professor CC was involved in the design, supervised the data analysis, and revised the manuscript.

Data availability The data that support the findings of this study are available from the corresponding author upon reasonable request.

Compliance with ethical standards

Conflict of interest None.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q et al (2015) Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril 104(1):62–703. https://doi.org/10.1016/j.fertnstert.2015.03.022
2. Huang J, Xie Q, Lin J, Lu X, Zhu J, Gao H et al (2019) Progestin-primed ovarian stimulation with dydrogesterone versus medroxyprogesterone acetate in women with polycystic ovarian syndrome for in vitro fertilization: a retrospective cohort study. Drug Design, Develop Ther. 13:4461–4470. https://doi.org/10.2147/DDDT.S231029
3. Iwami N, Kawamata M, Ozawa N, Yamamoto T, Watanabe E, Moriwaka O et al (2018) New trial of progestin-primed ovarian stimulation using dydrogesterone versus a typical GnRH antagonist regimen in assisted reproductive technology. Arch Gynecol Obstet 298(3):663–671. https://doi.org/10.1007/s00404-018-4856-8
4. Erfekhar M, Hoseini M, Saeed L (2019) Progesterone-primed ovarian stimulation in polycystic ovarian syndrome: an RCT. Int J Reprod Biomed 17(9):671–676. https://doi.org/10.18502/ijrmb.v17i9.5103
5. Peng Q, Cao X, Wang J, Wang L, Xu J, Ji X et al (2019) Progestin-primed ovarian stimulation vs mild stimulation in women with advanced age above 40: a retrospective cohort study. Reprod Biol Endocrinol: RB&E 17(1):91. https://doi.org/10.1186/s12958-019-0518-3
6. Zegers-Hochschild F, Adamson GD, de Mouzon J, Ishihara O, Mansour R, Nygren K et al (2009) International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) revised Glossary of ART terminology, 2009. Fertil Steril 92(5):1520–1524. https://doi.org/10.1016/j.fertnstert.2009.09.009
7. Chen Q, Chai W, Wang Y, Cai R, Zhang S, Lu X et al (2019) Progestin vs. Gonadotropin-releasing hormone agonist for the prevention of premature luteinizing hormone surges in poor responders undergoing in vitro fertilization treatment: a randomized controlled trial. Front Endocrinol 10:796. https://doi.org/10.3389/fendo.2019.00796
8. Begueria R, Garcia D, Vassena R, Rodriguez A (2019) Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Hum Reprod 34(5):872–880. https://doi.org/10.1093/humrep/dev034
9. Huang P, Tang M, Qin A (2019) Progestin-primed ovarian stimulation is a feasible method for poor ovarian responders undergoing in IVF/ICSI compared to a GnRH antagonist protocol: a retrospective study. J Gynecol Obstet Human Reprod 48(2):99–102. https://doi.org/10.1016/j.jogho.2018.10.008
10. Yildiz S, Turkgeldi E, Angun B, Erslan A, Urman B, Ata B (2019) Comparison of a novel flexible progestin primed ovarian stimulation protocol and the flexible gonadotropin-releasing hormone antagonist protocol for assisted reproductive technology. Fertil Steril 112(4):677–683. https://doi.org/10.1016/j.fertnstert.2019.06.009
11. Mathieu d’Argent E, Ferrier C, Zacharopoulou C, Ahdad-Yata N, Boudy AS, Cantalloube A et al (2020) Outcomes of fertility preservation in women with endometriosis: comparison of progestin-primed ovarian stimulation versus antagonist protocols. J Ovarian Res 13(1):18. https://doi.org/10.1186/s13048-020-00620-z
12. Wen X, Kuang Y, Zhou L, Yu B, Chen Q, Fu Y et al (2018) Lipidomic components alterations of human follicular fluid reveal the relevance of improving clinical outcomes in women using progestin-primed ovarian stimulation compared to short-term protocol. Med Sci Monitor: Int Med J Exp Clin Res 24:3357–3365. https://doi.org/10.12659/MSM.906602
13. Wang N, Lin J, Zhu Q, Fan Y, Wang Y, Fu Y et al (2018) Comparison of neonatal outcomes and live-birth defects after progestin-primed ovarian stimulation versus conventional ovarian stimulation for in vitro fertilization: a large retrospective cohort study. Medicine 97(34):e11906. https://doi.org/10.1097/MD.00000000000011906
14. Lu X, Hong Q, Sun L, Chen Q, Fu Y, Ai A et al (2016) Dual trigger for final oocyte maturation improves the oocyte retrieval rate of suboptimal responders to gonadotropin-releasing hormone agonist. Fertil Steril 106(6):1356–1362. https://doi.org/10.1016/j.fertnstert.2016.07.1068
15. Wang Y, Chen Q, Wang N, Chen H, Lyu Q, Kuang Y (2016) Controlled ovarian stimulation using medroxyprogesterone acetate and hMG in patients with polycystic ovary syndrome treated for IVF: a double-blind randomized crossover clinical trial. Medicine 95(9):e2939. https://doi.org/10.1097/MD.0000000000002939
16. Evans MB, Parikh T, DeCherney AH, Cskokmay JM, Healy MW, Hill MJ (2019) Evaluation of the cost-effectiveness of ovulation suppression with progestins compared with GnRH analogs in
assisted reproduction cycles. Reprod Biomed Online 38(5):691–698. https://doi.org/10.1016/j.rbmo.2018.12.044

17. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62(10):e1-34. https://doi.org/10.1016/j.jclinepi.2009.06.006

18. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https://doi.org/10.1136/bmj.d5928

19. Wells GA SB, O’Connell Dea (2008) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.oahp.ca/programs/clinical_epidemiology/oxfordasp

20. Cook DA, Reed DA (2015) Appraising the quality of medical education research methods: the Medical Education Research Study Quality Instrument and the Newcastle-Ottawa Scale-Education. Acad Med: J Assoc Am Med Colleges 90(8):1067–1076. https://doi.org/10.1097/ACM.0000000000000786

21. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924–926. https://doi.org/10.1136/bmj.39489.47034.7.AD

22. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558. https://doi.org/10.1002/sim.1186

23. Al-Inany HG, Abou-Setta AM, Aboulghar MA, Mansour RT, Serour GI (2008) Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH: a meta-analysis. Reprod Biomed Online 16(1):81–88. https://doi.org/10.1016/s1472-6483(10)60559-7

24. Coomarasamy A, Afnan M, Cheema D, van der Veen F, Bossuyt PM, van Wely M (2008) Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum Reprod 23(2):310–315. https://doi.org/10.1093/humrep/dex367

25. Jesus AR, Silva-Soares S, Silva J, Severo M, Barros A, Doria S (2019) Reproductive success of assisted reproductive technology in couples with chromosomal abnormalities. J Assist Reprod Genet 36(7):1471–1479. https://doi.org/10.1007/s10815-019-01486-x

26. Zhang J, Mao X, Wang Y, Chen Q, Lu X, Hong Q et al (2017) Neonatal outcomes and congenital malformations in children born after human menopausal gonadotropin and medroxyprogesterone acetate treatment cycles. Arch Gynecol Obstet 296(6):1207–1217. https://doi.org/10.1007/s00404-017-4537-z

27. Huang J, Xie Q, Liu J, Lu X, Wang N, Gao H et al (2019) Neonatal outcomes and congenital malformations in children born after dydrogesterone application in progestin-primed ovarian stimulation protocol for IVF: a retrospective cohort study. Drug Design, Dev Therap 13:2553–2563. https://doi.org/10.2147/DDDT.S210228

28. Yu S, Long H, Chang HY, Liu Y, Gao H, Zhu J et al (2018) New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum Reprod 33(2):229–237. https://doi.org/10.1093/humrep/dex367

29. Zhu X, Zhang X, Fu Y (2015) Utrogestan as an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Medicine 94(21):e909. https://doi.org/10.1097/MD.0000000000000909

30. Wang Y, Kuang Y, Chen Q, Cai R (2018) Gonadotropin-releasing hormone antagonist versus progestin for the prevention of premature luteinising hormone surges in poor responders undergoing in vitro fertilisation treatment: study protocol for a randomised controlled trial. Trials 19(1):455. https://doi.org/10.1186/s13063-018-2850-x

31. Levi Setti PE, Alviggi C, Colombo GL, Pisanelli C, Ripellino C, Longobardi S et al (2015) Human recombinant follicle stimulating hormone (rFSH) versus urinary human menopausal gonadotropin (HMG) for ovarian stimulation in assisted reproduction: a literature review and cost evaluation. J Endocrinol Invest 38(5):497–503. https://doi.org/10.1007/s40618-014-0204-4

32. Revello A, Pettinau G, Basso G, Carosso A, Ferrero A, Dallan C et al (2015) Controlled Ovarian Stimulation with recombinant-FSH plus recombinant-LH vs. human Menopausal Gonadotropin based on the number of retrieved oocytes: results from a routine clinical practice in a real-life population. Reprod Biol Endocrinol: RB&E 13:77. https://doi.org/10.1186/s12958-015-0080-6

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.